Kissei Pharmaceutical will grant a total of 19,794 shares of restricted share conveyance to directors and executive officers, with payment scheduled for July 23, 2026. The introduction of this system aims to enhance corporate value and shareholder value sharing.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4547","jir_company_name":"Kissei Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-06-23","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/06\/4547-20260623-01.pdf","jir_short_summary":"Kissei Pharmaceutical will grant a total of 19,794 shares of restricted share conveyance to directors and executive officers, with payment scheduled for July 23, 2026. The introduction of this system aims to enhance corporate value and shareholder value sharing.","jir_summary":"### Overview of the Disposition\nKissei Pharmaceutical plans to grant a total of 19,794 shares of restricted share conveyance to directors and executive officers, with payment scheduled for July 23, 2026. The disposal price is 3,940 yen per share, totaling 77,988,360 yen. This system aims to promote sustained enhancement of corporate value and shared value with shareholders. The targeted individuals will be subject to transfer restrictions for a certain period. Details of the system include restrictions on transfer periods, conditions for\u89e3\u9664, and provisions for gratuitous acquisition.\n\n### Purpose of the System and Future Outlook\nThis system aims to provide stock-based rewards to targeted individuals, fostering long-term commitment from officers and management. It was approved at the Shareholders' Meeting in June 2025, aiming to improve corporate value while minimizing shareholder dilution. The payment amount will be determined based on market stock prices, and the system is expected to enhance incentives for officers, supporting the company's sustainable growth.","jir_financial_highlights":"Number of Shares Disposed: 19,794 shares (Unknown)\nDisposal Price: 77,988,360 yen (Unknown)\nPayment Amount Per Share: 3,940 yen (Unknown)","jir_category":"","jir_hashtags":"#KisseiPharmaceutical, #IRRelated, #JapaneseStocks","jir_key_figures":"Number of Shares Disposed: 19,794 shares\nDisposal Price: 77,988,360 yen\nPayment Amount Per Share: 3,940 yen","jir_meta_title":"\u3010Kissei Pharmaceutical\u3011Share Buyback and Compensation System Introduction \uff5c June 2026","jir_meta_description":"Kissei Pharmaceutical will grant a total of 19,794 shares of treasury stock to directors and executive officers in July 2026. This report explains the purpose and details of the system implementation.","jir_og_title":"\u3010Kissei Pharmaceutical\u3011Share Buyback and Compensation System Introduction \uff5c June 2026","jir_og_description":"Kissei Pharmaceutical promotes corporate value enhancement and shareholder value sharing by granting treasury stocks to officers. Detailed information is also included.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":8930,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"share_cancellation","footnotes":""},"sector":[],"importance":[],"class_list":["post-67574","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n